Skip to Content

Steven H. Lin, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Faculty, Graduate School of Biomedical Sciences, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

I am a Physician-Scientist and Radiation Oncologist who specialize in thoracic malignancies. My laboratory is committed to developing approaches that will enhance traditional cancer therapies. We have developed a novel radiation sensitizer screen approach to identify in a high throughput manner targeted therapies that could immediately be translated to the clinical setting. Through this effort, two phase I clinical trials have been launched and accruing as a direct result of this research. We continue to apply novel approaches to identify other drivers of treatment resistance, and seek innovative strategies to counterbalance the resistance mechanisms. We are applying candidate gene knockdown or knockout screens to identify immunomodulators or radiation sensitivity modulators. Our focus is on clinical translation, taking potential drug candidates and testing them in preclinical studies to validate the utility of combining radiation sensitizers or immunomodulators with standard of care chemoradiotherapy or radiotherapy alone approaches for the management of lung and esophageal cancer. Promising agents are brought to the clinic as investigator-initiated trials.   

Research Interests

My laboratory has several lines of research.  The first is to identify novel agents to combine with radiation to enhance treatment effects through the application of high throughput screening methods.  Second, I am interested in identifying novel gene targets that could enhance the systemic immune response in combination with radiation therapy.  Third, I am seeking ways through imaging or blood based markers to assess response to treatment for lung and esophageal cancer patients. 

Clinical Interests

My clinical interests lie in improving the clinical outcomes of lung and esophageal cancer patients receiving radiation therapy.  I have a special interest in the application of advanced radiation technologies such as Intensity Modulated Radiation Therapy (IMRT) and proton beam therapy as a way to minimize toxicity and improve clinical outcomes for esophageal cancer patients.  I also have interest in using various imaging and blood based biomarkers to predict response to treatment.

Education & Training

Degree-Granting Education

2004 University of California, Irvine, CA, MD, Medicine
2004 University of California, Irvine, CA, PHD, Pharmacology
1995 University of California, Riverside, CA, MS, Biochemistry
1994 University of California, Riverside, CA, BS, Biology
1992 California Polytechnic University, Pomona, CA, None, Architecture (transferred)

Postgraduate Training

7/2005-8/2009 Clinical Residency, Radiation Oncology, The John Hopkins Hospital, Baltimore, MD, Ted L. DeWeese
7/2004-6/2005 Clinical Internship, Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA
6/2001-7/2002 Post-Ph.D., Neuropharmacology, Neogene Technologies, Irvine, CA, Olivier Civelli

Board Certifications

5/2010 American Board of Radiology


Institutional Committee Activities

Vice Chair, Institutional Review Board 5, 9/2015-present
Vice Chair, Institutional Research Grant Committee-Basic Study Section Committee, 9/2015-present

Honors and Awards

2012-2014 Comparative Effectiveness Research on Cancer in Texas Fellow, CERCIT
2010-2013 ASTRO Junior Faculty Fellow, American Society for Radiation Oncology (ASTRO)
2008-2009 RSNA Research Resident Grant
2008 ABS/Nucletron HDR Brachytherapy Fellowship
2004 Alpha Omega Alpha, University of California, Irvine School of Medicine
2001 Henry Wood Elliott Award in Pharmacology
1998 American Heart Association Medical Student Fellowship
1997 UC Regents Research Fellowship
1996-1997 Dean's Award, University of California, Irvine School of Medicine
1996 Donald E. Pinder, M.D. Memorial Award
1996 Dr. Grace Bell Award
1995-2004 Medical Scientist Training Program Fellowship and Stipend
1994 Phi Beta Kappa, University of California
1994 Summa Cum Laude, University of California

Selected Publications

Peer-Reviewed Original Research Articles

1. van Rossum PSN, Fried DV, Zhang L, Hofstetter WL, Ho L, Meijer GJ, Carter BW, Court LE, Lin SH,. The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in esophageal adenocarcinoma. Eur J Nucl Med Mol Imaging. In Press.
2. Wang Y, Liu H, Diao L, Potter A, Zhang J, Qiao Y, Wang J, Proia DA, Tailor R, Komaki R, Lin SH,. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Clin Cancer Res. e-Pub 6/2016.
3. Chuong MD, Hallemeier CL, Jabbour SK, Yu J, Badiyan S, Merrell KW, Mishra MV, Li H, Verma V, Lin SH. Improving Outcomes for Esophageal Cancer using Proton Beam Therapy. Int J Radiat Oncol Biol Phys 95(1):488-497, 5/2016. e-Pub 12/2015. PMID: 27084662.
4. van Rossum PS, Fried DV, Zhang L, Hofstetter WL, van Vulpen M, Meijer GJ, Court LE, Lin SH. The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer. J Nucl Med 57(5):691-700, 5/2016. e-Pub 1/2016. PMID: 26795288.
5. Li N, Feng L, Liu H, Wang J, Kasembeli M, Tran MK, Tweardy DJ, Lin SH, Chen J. PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Cell Rep. e-Pub 4/2016. PMID: 27149849.
6. Yu J, Zhang X, Liao L, Li H, Zhu R, Park PC, Sahoo N, Gillin M, Li Y, Chang JY, Komaki R, Lin SH. Motion-robust intensity modulated proton therapy for distal esophageal cancer. Med Phys 43(3):1111, 3/2016. PMID: 26936698.
7. Lin SH, Zhang N, Godby J, Wang J, Marsh GD, Liao Z, Komaki R, Ho L, Hofstetter WL, Swisher SG, Mehran RJ, Buchholz TA, Elting LS, Giordano SH. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer 122(6):917-928, 3/2016. e-Pub 12/2015. PMID: 26716915.
8. Hobbs BP, Thall PF, Lin SH. Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival. J R Stat Soc Ser C Appl Stat 65(2):273-297, 2/2016. e-Pub 10/2015. PMCID: PMC4809549.
9. Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. e-Pub 2/2016. PMID: 26891607.
10. Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila) 8(11):1027-1035, 11/2015. e-Pub 9/2015. PMCID: PMC4777304.
11. van Rossum PS, van Lier AL, van Vulpen M, Reerink O, Lagendijk JJ, Lin SH, van Hillegersberg R, Ruurda JP, Meijer GJ, Lips IM. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer. Radiother Oncol 115(2):163-170, 5/2015. e-Pub 5/2015. PMID: 26002307.
12. Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of Simultaneous Radiation Boost Achieves High Control Rates in Patients With Non-Small-Cell Lung Cancer Who Are Not Candidates for Surgery or Conventional Chemoradiation. Clin Lung Cancer 16(2):156-163, 3/2015. e-Pub 10/2014. PMID: 25467928.
13. Wang J, Palmer M, Bilton SD, Khoi VN, Greer S, Frame R, Liao Z, Komaki R, Cox JD, Lin SH. Comparing Proton Beam to Intensity Modulated Radiation Therapy Planning in Esophageal Cancer. Int J Particle Ther. e-Pub 2/2015.
14. Lin SH, Wang J, Allen PK, Correa AM, Maru D, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. Nomogram for Pathologic Complete Response to Neoadjuvant Chemoradiation also Predicts Survival Outcomes after Definitive Chemoradiation for Esophageal Cancer. J Gastro Oncol 6(1):45-52, 2/2015. PMCID: PMCPMC4294819.
15. Guan F, Bronk L, Titt U, Lin SH, Mirkovic D, Kerr MD, Zhu XR, Dinh J, Sobieski M, Stephan C, Peeler CR, Taleei R, Mohan R, Grosshans DR. Spatial mapping of the biologic effectiveness of scanned particle beams: towards biologically optimized particle therapy. Sci Rep 5(9850):1-10, 2015. e-Pub 5/2015. PMCID: PMC4650781.
16. Lin SH, Wang J, Saintigny P, WuCC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, Wistuba II, Date H, Minna JD, Heymach JV. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics 15, 12/2014. PMID: 25486910.
17. Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, Pan HY, Chang JY, Komaki R, Cox JD, McAleer MF, Grosshans DR. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol 9(10):1551-60, 10/2014. PMCID: PMCPMC4273574.
18. He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. J Thorac Oncol 9(9):1398-1405, 9/2014. PMID: 25122435.
19. Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, Ajani JA, Swisher SG, Maru DM. Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation. Ann Thorac Surg 98(3):1064-1071, 9/2014. e-Pub 7/2014. PMID: 25038008.
20. Lin SH, Zhang J, Giri U, Stephan C, Sobieski M, Zhong L, Mason KA, Molkentine J, Thames HD, Yoo SS, Heymach JV. A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non-Small Cell Lung Cancer. J Thorac Oncol 9(7):965-973, 7/2014. PMCID: PMC4110054.
21. Wang J, Suri JS, Allen PK, Liao Z, Komaki R, Ho L, Hofstetter WL, Lin SH. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer. Am J Clin Oncol. e-Pub 4/2014. PMID: 24710122.
22. Juloori A, Tucker SL, Komaki R, Liao Z, Correa AM, Swisher SG, Hofstetter WL, Lin SH. Influence of preoperative radiation field on postoperative leak rates in Esophageal cancer patients after trimodality therapy. J Thorac Oncol 9(4):534-540, 4/2014. PMCID: PMC3989552.
23. Ly NB, Allen PK, Lin SH. Stereotactic body radiation therapy for stage I small cell lung cancer: a single institutional case series and review of the literature. J Radiat Oncol. e-Pub 3/2014.
24. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for Esophageal Carcinoma. Dis Esophagus 27(2):168-175, Feb-Mar, 2/2014. e-Pub 4/2013. PMCID: PMC3740061.
25. Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X,Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, Kurie JM. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 124:2696-2708, 2014.
26. Zhang X, Lin SH, Fang B, Gillin M, Mohan R, Chang JY. Therapy resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. J Thorac Oncol 8(12):1484-1491, 12/2013. PMCID: PMC3882687.
27. Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys 86(5):885-891, 8/2013. PMCID: PMC3786201.
28. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-1009, 6/2013. e-Pub 9/2012. PMID: 22950385.
29. Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 24(5):1262-1266, 5/2013. e-Pub 12/2012. PMCID: PMC3629896.
30. Wu CC, Kannan K,Lin SH,Yen L, Milosavlijevic A. Identification of cancer fusion drivers using network fusion centrality. Bioinformatics. e-Pub 5/2013.
31. Lin SH, George T, Ben-Josef E, Bradley J, Choe K, Edelman MJ, Guha C, Krishnan S, Lawrence T, Le QT, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver MX, Coleman N, Vikram B, Yoo S, Chung C. Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. J Natl Cancer Inst. e-Pub 3/2013.
32. Lopez Guerra JL, Gomez DR, Lin SH, Levy LB, Zhuang Y, Komaki R, Jaen J, Vaporciyan AA, Swisher SG, Cox JD, Liao Z, Rice DC. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol 24(1):67-74, 1/2013. e-Pub 9/2012. PMCID: PMC3525136.
33. Armini A, Feiran L, Corea AM, Baldessare R, Rimner A, Huang J, Roth JA, Swisher SG, Vaporciyan AA,Lin SH. Predictors for locoregional recurrence for clinical stage III-N2 non-small cell lung cancer with nodal downstaging after induction chemotherapy and surgery. Ann Surg Oncol 20:1934-40, 2013.
34. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J,Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer 48(18):3396-33404, 12/2012. e-Pub 7/2012. PMCID: PMC3869451.
35. Lin SH, Myles B, Wang L, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score based comparison of long term outcomes with 3D conformal radiotherapy (3DCRT) versus Intensity Modulated Radiation Therapy (IMRT) in treatment of esophageal cancer. Int J Radiat Oncol Biol Phy 84(5):1078-85, 12/2012. PMID: 22867894.
36. Saintigny P, Massarelli E,Lin SH, Ahn YH, Chen Y, Goswani S, Erez B. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Research, 11/2012. e-Pub 11/2012.
37. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 23(10):2638-2642, 10/2012. e-Pub 7/2012. PMCID: PMC3457750.
38. Xu T, Wei Q, Lopez Guerra JL, Wang LE, Liu Z, Gomez D, O'Reilly M,Lin SH, Zhuang Y, Levy LB, Mohan R, Zhou H, Liao Z. HSPB1 Gene Polymorphisms Predict Risk of Mortality for US Patients After Radio(chemo)therapy for Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 84(2):e229-e235, 10/2012. e-Pub 5/2012. PMCID: PMC3426644.
39. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus 25(7):614-622, 9/2012. e-Pub 12/2011. PMID: 22150920.
40. Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, Swisher SG, Rice DC, Vaporciyan AA,Lin SH. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg 94(3):914-920, 9/2012. e-Pub 7/2012. PMID: 22819472.
41. Yu ZH, Lin SH, Balter P, Zhang L, Dong L. A comparison of tumor motion characteristics between early stage and locally advanced stage lung cancers. Radiother Oncol 104(1):33-38, 7/2012. e-Pub 6/2012. PMID: 22677039.
42. Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 83(3):e345-e351, 7/2012. e-Pub 3/2012. PMID: 22417808.
43. Wang J, Lin SH, Dong L, Balter P, Mohan R, Komaki R, Cox JD, Starkschall G. Quantifying the Interfractional Displacement of the Gastroesophageal Junction during Radiation Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 83(2):e273-e280, 6/2012. e-Pub 3/2012. PMID: 22440040.
44. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology 82(2):108-113, 2012. e-Pub 2/2012. PMID: 22328056.
45. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation. Oncology 83(5):300-304, 2012. e-Pub 9/2012. PMCID: PMC3832345.
46. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4822-4833, 11/2011. e-Pub 3/2011. PMCID: PMC3144261.
47. Liao Z, Lin SH, Cox JD. Status of Particle therapy for lung cancer. Acta Oncol 50(6):745-756, 8/2011. PMID: 21767170.
48. Hristov B, Reddy S,LinSH, Cameron JL, Pawlik TM, Hruban RH, Swartz MJ, Edil BH, Kemp C, Wolfgang CL, Herman JM. Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 76(1):176-180, 1/2010. PMID: 19394156.
49. Tan AC, Jimeno A,Lin SH, Wheelhouse J, Chan F, Solomon A, Rajeshkumar NV, Rubio-Viqueira B, Hidalgo M. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 3(5-6):425-438, 12/2009. e-Pub 4/2009. PMID: 19497796.
50. Yi JM, Tsai HC, Glöckner SC,Lin SH, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE, Baylin SB. Abnormal DNA methylation of CD133 in Colorectal and Glioblastoma Tumors. Cancer Res 68(19):8094-8103, 10/2008. PMCID: PMC2744404.
51. Lin SH, Sugar E, Teslow T, McNutt T, Saleh H, Song DY. Comparison of daily couch shifts using MVCT (TomoTherapy) and B-mode Ultrasound (BAT system) during prostate radiotherapy. Technol Cancer Res Treat 7(4):279-286, 8/2008. PMID: 18642966.
52. Lin SH, Kleinberg LR. Carmustine Wafers: Localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8(3):343-359, 3/2008. PMID: 18366283.
53. Lin SH, Latronico D, Teslow T, Bajaj GK. A highly reproducible bolus immobilization technique for the treatment of scalp malignancies. Med Dosim 33(1):30-35, 2008. PMID: 18262120.
54. Lin SH. Prolactin Releasing Peptide. Results Probl Cell Differ 46:57-88, 2008. PMID: 18204826.
55. Nagasaki H, Wang Z, Jackson VR,Lin SH, Nothacker HP, Civelli O. Differential expression of the thyrostimulin subunits, glycoprotein alpha2 and beta5 in the rat pituitary. J Mol Endocrinol 37(1):39-50, 8/2006. PMID: 16901922.
56. Jackson VR, Lin SH, Wang Z, Nothacker HP, Civelli O. A study of the rat neuropeptide B/neuropeptide W system using in situ techniques. J Comp Neurol 497(3):367-383, 7/2006. PMID: 16736466.
57. Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z,Lin SH, Brucher FA, Zeng J, Ly NK, Henriksen SJ, de Lecea L, Civelli O. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43(4):487-497, 8/2004. PMID: 15312648.
58. Lin SH, Civelli O. Orphan G protein-coupled receptors: targets for new therapeutic interventions. Ann Med 36(3):204-214, 2004. PMID: 15181976.
59. Civelli O, Nothacker HP, Saito Y, Wang Z, Lin SH, Reinscheid RK. Novel neurotransmitters as natural ligands of orphan G protein-coupled receptors. Trends Neurosci 24(4):230-237, 4/2001. PMID: 11250008.
60. Nothacker HP, Wang Z, Zhu Y, Reinscheid RK,Lin SH, Civelli O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol 58(6):1601-1608, 2000. PMCID: PMC1193801.
61. Saito Y, Nothacker HP, Wang Z, Lin SH, Leslie F, Civelli O. Molecular characterization of the melanin-concentrating hormone receptor. Nature 400(400):265-269, 7/1999. PMID: 10421368.

Book Chapters

1. Lin SH, Komaki R. Molecular Targeted Treatment for Personalized Radiotherapy in Lung Cancer. In: Lung Cancer, 4th Edition. Ed(s) JA Roth, WK Hong, R Komaki. John Wiley & Sons, Inc, 2014.
2. Lin SH, Liao Z. Esophageal Cancer. In: Decision Making in Radiation Oncology, 2nd Edition. Ed(s) Lu JJ, Brady LW. Springer-Verlag: Heidelberg, Germany, 329-358, 2010.
3. Lin SH, Chang JY. Lung Cancer. In: Decision Making in Radiation Oncology, 2nd Edition. Ed(s) Lu JJ, Brady LW. Springer-Verlag: Heidelberg, Germany, 261-307, 2010.

Books (edited and written)

1. Hristov B, Lin SH, Christodouleas JP. Ed(s) Hristov B, Lin SH, Christodouleas JP. Radiation Oncology: A Question-based Review. In: Radiation Oncology: A Question-based Review, 2nd edition. Wolters Kluwer, Lippincott, Williams & Wilkins: Germany, 2014.
2. Hristov B, Lin SH, Christodouleas JP. Ed(s) Hristov B, Lin SH, Christodouleas JP. Radiation Oncology: A Question-based Review. In: Radiation Oncology: A Question-based Review, 1st Edition. Wolters Kluwer, Lippincott, Williams & Wilkins: Germany, 2011.

Grant & Contract Support

Title: GUARDIAN-1 Trial: A Phase I Study of Genetespib in Combination with Chemoradiation for Stage II-III Esophageal Carcinoma
Funding Source: Synta Pharmaceuticals
Role: Principal Investigator
Duration: 4/1/2015 - 3/31/2016
Title: Diffusion-weighted magnetic reasonance imaging for early response assessment of neoadjuvant chemoradiation therapy in patients with esophgeal carcinoma
Funding Source: UTMDACC
Role: Co-Investigator
Principal Investigator: Dr. Zhongxing Liao
Duration: 1/1/2015 - 12/31/2016
Title: Radiogenomic Predictor of Pathologic Response and Recurrence in Esophageal Cancer Patients
Funding Source: R. Lee Clark Fellowship
Role: Principal Investigator
Duration: 7/1/2014 - 6/30/2016
Title: University of Texas SPORE in Lung Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: John Minna and Jack Roth
Duration: 2014 - 2019
Title: Phase I trial combining trametinib with chemoradiation in Kras mutant lung cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 11/1/2013 - 10/31/2015
Title: Research and Development of Novel Radiation Sensitizers
Funding Source: STCube Pharmaceuticals Inc.
Role: Principal Investigator
Duration: 10/1/2013 - 9/30/2016
Title: Transcriptomic Correlates of Pathologic Complete Response and Residual Disease after Neoadjuvant Chemoradiation in Esophageal Cancer
Funding Source: MD Anderson Cancer Center
Role: Principal Investigator
Duration: 8/1/2013 - 1/31/2015
Title: Functional Magnetic Resonance Imaging for Response Assessment to Chemoradiation in Esophageal Cancer
Funding Source: Elekta LLC
Role: Principal Investigator
Duration: 7/1/2013 - 1/31/2015
Title: High Throughput Synthetic Lethal Drug Screen to Identify Novel Radiation Sensitizers for Kras Mutant Non-Small Cell Lung Cancer
Funding Source: MD Anderson Cancer Center
Role: Principal Investigator
Duration: 7/1/2013 - 1/31/2015
Title: Improving Our Understanding and Maximizing the Effectiveness of Proton Therapy”
Funding Source: Center for Radiation Oncology Research
Role: Co-Principal Investigator
Duration: 7/1/2013 - 6/30/2014
Title: Kras mutation targeting to enhance radiation response in non-small cell lung cancer
Funding Source: Uniting Against Lung Cancer
Role: Principal Investigator
Duration: 3/1/2013 - 2/28/2015
Title: Molecular Predictors of Radiation Resistance in Postoperative Radiation Patients
Funding Source: MDACC Lung Cancer Priority Program
Role: Principal Investigator
Duration: 10/1/2011 - 9/30/2014
Title: Investigating the Prognostic Significance of Circulating Tumor Cells in Epithelial Mesenchymal Transition in Lung Cancer Patients During and After Chemoradiation
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 10/1/2011 - 9/30/2012
Title: Predicting Metastasis and Primary Radiation Resistance Using a DNA Methylation Signature for Epithelial-to-Mesenchymal Transition in Non-Small Cell Lung Cancer Patients
Funding Source: American Society for Therapeutic Radiology and Oncology (ASTRO)
Role: Principal Investigator
Duration: 7/1/2010 - 6/30/2012
Title: Methylation Biomarker Profiling for Chemotherapy Response in Non-Small Cell Lung
Funding Source: University of Texas SPORE in Lung Cancer
Role: Principal Investigator
Duration: 1/1/2010 - 12/31/2010

Last updated: 8/17/2016